Latest research on Valsartan

Valsartan is an angiotensin-receptor blocker (ARB) that may be used to treat a variety of cardiac conditions including hypertension, diabetic nephropathy and heart failure. Valsartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Valsartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.

Valsartan and alcohol

Key exclusion criteria included a contraindication to β-blockers or ARBs, a resting SBP of ≤90 or ≥140 mm Hg or DBP of <50 or ≥90 mm Hg, abnormal electrocardiogram results or QT interval prolongation (QTcF ≥430 ms for men or ≥450 ms for women), consumption of grapefruit or caffeine-containing products within 48 hours or alcohol within 72 hours before study drug administration, conditions that could affect the pharmacokinetics or pharmacodynamics of Nebivolol or Valsartan, concomitant medication use within 14 days or hormonal medications within 30 days before study drug administration, previous use of Nebivolol or Valsartan, identification as poor metabolizer (by means of CYP2D6 genotyping), serum sodium levels of <135–145 mEq/L, serum potassium levels of ≥5.3 mEq/L, or current pregnancy or breastfeeding. [source, 2015]